ESC Congress 2024 Clinical Trials to Watch, with Deepak Bhatt, MD, MPH, MBA

Although both the American College of Cardiology and American Heart Association annual meetings are held in high esteem and renowned as platforms for sharing the latest clinically impactful and relevant research findings in cardiology, it is their European-based counterpart, the European Society of Cardiology (ESC), that boasts the title of largest annual cardiology meeting.

An annual gathering of more than 30,000 professionals interested in cardiology from across the globe, the meeting has served as a showcase for breakthroughs and discoveries across a plethora of cardiovascular disciplines and subspecialties. The ESC Congress 2024 will be a continuation of this trend. Hosted in London from August 30 through September 1, 2024, the meeting will feature 12 Hot Line sessions encompassing dozens of novel data releases from major clinical trial programs, including FINEARTS-HF, OCEANIC-AF, and more.

A leading subject matter expert in cardiology, Deepak Bhatt, MD, MPH, MBA, director of Mount Sinai Heart, is among the meetings planned attendees and presenters. For more insight into what trials he is looking forward to and why, the editorial team of HCPLive Cardiology interviewed Bhatt to learn what trials he was most looking forward to from the forthcoming meeting. That conversation is the subject of the video featured above. For a rundown of Bhatt’s picks and when they are scheduled to be presented, check out our list below.

• FINEARTS-HF: Hot Line 7 on Sunday, September 1 at 11:00 AM BST
  • Description: Phase 3 trial of finerenone in patients with heart failure with preserved ejection fraction.
• EMPACT-MI KIDNEY: Late-Breaking Science on Sunday, September 1 at 09:00 AM BST
  • Description: Analysis of the EMPACT-MI trial evaluating the safety of initiating SGLT2 inhibition in ACS patients from a kidney perspective.
• ABYSS trial: Hot Line 1 on Friday, August 30 at 11:00 AM BST
  • Description: Trial evaluating the cardiovascular safety of beta-blocker interruption in stabilized post-MI patients without heart failure nor reduced LVEF.
• STOP-OR-NOT: Hot Line 1 on Friday, August 30 at 11:00 AM BST
  • Description: Trial examining whether to stop renin-angiotensin system blockade before surgery to prevent post-operative complications.
• RESHAPE-HF2: Hot Line 3 on Saturday, August 31 at 11:00 AM BST
  • Description: Trial focusing on percutaneous repair of functional mitral regurgitation in heart failure patients.
• NOTION-3: Hot Line 5 on Saturday, August 31 at 5:35 PM BST
  • Description: Trial aiming at comparing FFR-guided revascularization vs medical treatment of CAD in patients with severe aortic stenosis planned for TAVI
• SHAM-PVI: Hot Line 1 on Monday, September 2 at 11:00 AM BST
  • Description: Study comparing PV isolation using cryoablation to a sham procedure to estimate the effect of PV isolation on AF burden.

Relevant disclosures for Bhatt include Amarin, AstraZeneca, Sanofi, Pfizer, Roche, Amgen, and Eli Lilly and Company, among others.

References:

1. Meeting Media Group. London to host the world’s biggest cardiology conference in 2024. Meeting Media Group. March 30, 2021. Accessed August 14, 2024. https://meetingmediagroup.com/article/london-to-host-the-world-s-biggest-cardiology-conference-in-2024.
2. European Society of Cardiology. Hot Lines revealed – what everyone will be talking about at ESC congress 2024. European Society of Cardiology. July 30, 2024. Accessed August 14, 2024. https://www.escardio.org/The-ESC/Press-Office/Press-releases/Hot-Lines-revealed-what-everyone-will-be-talking-about-at-ESC-Congress-2024.